Apellis Pharmaceuticals Inc.

5 months ago · zacks.com

The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

5 months ago · zacks.com

Apellis Pharmaceuticals, Inc. (APLS) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.38 per share. This compares to a loss of $0.74 per share a year ago.

6 months ago · defenseworld.net

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS - Get Free Report) have received an average recommendation of "Hold" from the twenty-three brokerages that are currently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, seventeen have issued a hold recommendation and four have issued a buy recommendation on the

6 months ago · globenewswire.com

MILWAUKEE, April 07, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Apellis (NASDAQ: APLS) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Biogen.

6 months ago · prnewswire.com

NEW YORK, April 1, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Apellis Pharmaceuticals, Inc. (NASDAQ:  APLS ) related to its sale to Biogen, Inc. Under the terms of the proposed transaction, Apellis shareholders are expected to receive $41.00 per share in cash and a non-transferable contingent value right for the right to receive two payments of $2.00 per share each, contingent on certain annual global net sales thresholds being met for SYFOVRE.

6 months ago · zacks.com

Apellis Pharmaceuticals (APLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

6 months ago · businesswire.com

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Apellis Pharmaceuticals, Inc. (NasdaqGS: APLS) to Biogen Inc. (NasdaqGS: BIIB). Under the terms of the proposed transaction, shareholders of Apellis will receive $41.00 per share in cash and a nontransferable contingent value right for the right to receive two payments of $2.00 per share each, contin.

6 months ago · prnewswire.com

MILWAUKEE, March 31, 2026 /PRNewswire/ -- Ademi LLP is investigating Apellis (NASDAQ: APLS) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Biogen. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.

6 months ago · prnewswire.com

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws

6 months ago · barrons.com

A small biopharmaceutical firm was getting a big boost Tuesday after Biogen agreed to buy it for $5.6 billion.